Intraoperative anti-thymocyte globulin-fresenius (ATG-F) administration as induction immunosup+-pressive therapy in kidney transplantation

Molecular Immunology

Volumn 39, Issue 17-18, 2003, Pages 1089-1094

  Abou Jaoude, Maroun M ^a   Almawi, Wassim Y ^b  

^a SAINT GEORGE HOSPITAL UNIVERSITY MEDICAL CENTER   (Lebanon)

^b ARABIAN GULF UNIVERSITY   (Bahrain)

Author keywords

Anti thymocyte globulin fresenius; Induction immunosuppressive therapy; Kidney transplantation

Indexed keywords

AZATHIOPRINE; BLOOD CLOTTING FACTOR 5 LEIDEN; CREATININE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; AGED; ANEMIA; CADAVER DONOR; CANDIDIASIS; CATHETER INFECTION; CHRONIC GLOMERULONEPHRITIS; CHRONIC PYELONEPHRITIS; CLINICAL ARTICLE; CONFERENCE PAPER; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; FEMALE; FEVER; FOLLOW UP; GRAFT FAILURE; HERPES; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; LUNG ASPERGILLOSIS; MALE; MUTATION; MYCOSIS; ORGAN DONOR; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; STATISTICAL ANALYSIS; THROMBOCYTOPENIA; THROMBUS; TREATMENT INDICATION; TREATMENT WITHDRAWAL; URINARY TRACT INFECTION;

BACTERIA (MICROORGANISMS); HERPES;

EID: 0038094472     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-5890(03)00071-3     Document Type: Conference Paper

References (29)

1. Agha I.A., Rueda J., Alvarez A., Singer G.G., Miller B.W., Flavin K., Lowell J.A., Shenoy S., Howard T.K., Ramachandran V., Irish W., Schnitzle M.A., Brennan D.C. Short course induction immunosuppression with thymoglobulin for renal transplant recipients. Transplantation. 73:2002;473-475.
2. Bertoni E., Maccario M., Biagini M., Montagnino G., Piperno R., Tarantino A., Salvadori M. Efficacy and safety of anti-thymocyte globulin treatment of steroid-resistant acute rejection in kidney transplantation. Transplant. Proc. 33:2001;3337.
3. Bock H.A., Gallati H., Zurcher R.M., Bachofen M., Mihatsch M.J., Landmann J., Thiel G. A randomized prospective trial of prophylactic immunosuppression with ATG-fresenius versus OKT3 after renal transplantation. Transplantation. 59:1995;830-840.
4. Brennan D.C., Schnitzler M.A., Baty J.D., Ceriotti C.S., Lowell J.A., Shenoy S., Howard T.K., Woodward R.S. A pharmaco-economic comparison of anti-thymocyte globulin and muromonab CD3 induction therapy in renal transplant recipients. Pharmacoeconomics. 11:1997;237-245.
5. Cantarovich D., Giral-Classe M., Hourmant M., Dantal J., Blancho G., Karam G., Soulillou J.P. Low incidence of kidney rejection after simultaneous kidney-pancreas transplantation after anti-thymocyte globulin induction and in the absence of corticosteroids: results of a prospective pilot study in 28 consecutive cases. Transplantation. 69:2000a;1505-1508.
6. Cantarovich D., Giral-Classe M., Hourmant M., Dantal J., Blancho G., Lerat L., Moreau A., Soulillou J.P. Prevention of acute rejection with anti-thymocyte globulin, avoiding corticosteroids, and delaying cyclosporin after renal transplantation. Nephrol. Dial. Transplant. 15:2000b;1673-1676.
7. Charpentier B. Induction versus non-induction protocols in anti-calcineurin-based immunosuppression. Transplant. Proc. 33:2001;3334-3336.
8. Cole E.H., Cattran D.C., Farewell V.T., Aprile M., Bear R.A., Pei Y.P., Fenton S.S., Tober J.A., Cardella C.J. A comparison of rabbit anti-thymocyte serum and OKT3 as prophylaxis against renal allograft rejection. Transplantation. 57:1994;60-67.
9. Filo R.S., Smith E.J., Leapman S.B. Therapy of acute renal allograft rejection with adjunctive anti-thymocyte globulin. Transplantation. 30:1980;445-449.
10. First M.R. An update on new immunosuppressive drugs undergoing pre-clinical and clinical trials: potential applications in organ transplantation. Am. J. Kidney Dis. 29:1997;303-317.
11. Greger B., Reis H.J., Mellert J., Schareck W.D., Muller G.H., Hopt U.T., Bockhorn H. Rejection treatment by polyclonal antibodies in kidney transplantation: reliable therapy without severe side effects. Transplant. Proc. 20:1988;9-11.
12. Hricik D.E., Almawi W.Y., Strom T.B. Trends in the use of glucocorticoids in renal transplantation. Transplantation. 57:1994;979-989.
13. Kaden J. Effect of ATG-prophylaxis in sensitized and non-sensitized kidney graft recipients. Transplant. Int. 5(1):1992;75-78.
14. Kaden J. Intraoperative high-dose anti-T-lymphocyte globulin bolus in addition to triple-drug therapy improves kidney graft survival. Transplant. Proc. 27:1995;1060-1061.
15. Kahan B.D. Cyclosporine. New Engl. J. Med. 321:1989;1725-1738.
16. Kahn D., Botha J.F., Pascoe M.D., Pontin A.R., Halkett J., Tandon V. Withdrawal of cyclosporine in renal transplant recipients with acute tubular necrosis improves renal function. Transplant. Int. 13(1):2000;S82-S83.
17. Killick S.B., Marsh J.C., Booth J.C., Gordon-Smith E.C. Liver function abnormality following treatment with anti-thymocyte globulin for aplastic anaemia. Bone Marrow Transplant. 19:1997;249-251.
18. Land W. Clinical immunosuppressive matrix in organ transplantation. Transplant. Proc. 25:1994;2479-2484.
19. Lange H., Muller T.F., Ebel H., Kuhlmann U., Grebe S.O., Heymanns J., Feiber H., Riedmiller H. Immediate and long-term results of ATG induction therapy for delayed graft function compared to conventional therapy for immediate graft function. Transpl. Int. 12:1999;2-9.
20. Lechevallier E., Dussol B., Luccioni A., Thirion X., Vacher-Copomat H., Jaber K., Brunet P., Leonetti F., Lavelle O., Coulange C., Berland Y. Post-transplantation acute tubular necrosis: risk factors and implications for graft survival. Am. J. Kidney Dis. 32:1998;984-991.
21. Malinow L., Walker J., Klassen D., Oldach D., Schweitzer E., Bartlett S.T., Weir M.R. Anti-lymphocyte induction immunosuppression in the post-Minnesota anti-lymphocyte globulin era: incidence of renal dysfunction and delayed graft function. A single center experience. Clin. Transplant. 10:1996;237-242.
22. Mariat C., Alamartine E., Diab N., de Filippis J.P., Laurent B., Berthoux F. A randomized prospective study comparing low-dose OKT3 to low-dose ATG for the treatment of acute steroid-resistant rejection episodes in kidney transplant recipients. Transpl. Int. 11:1998;231-236.
23. Matas A.J., Tellis V.A., Quinn T., Glichlick D., Soberman R., Weiss R., Karwa G., Veith F.J. ALG treatment of steroid-resistant rejection in patients receiving cyclosporine. Transplantation. 41:1986;579-583.
24. Muller T., Ruffingshofer D., Bidmon B., Arbeiter K., Balzar E., Aufricht C. Reduction of delayed renal allograft function using sequential immunosuppression. Pediatr. Nephrol. 16:2001;613-617.
25. Samsel R., Chmura A., Wlodarczyk Z., Wyzgal J., Cieciura T., Lagiewska B., Pliszczynski J., Korczak G., Lazowski T., Paczek L., Walaszewski J., Lao M., Rowinski W. Perioperative single high-dose ATG-fresenius S administration as induction immunosuppressive therapy in cadaveric renal transplantation: preliminary results. Ann. Transplant. 4:1999;37-39.
26. Schroeder T.J., Weiss M.A., Smith R.D. The efficacy of OKT3 in vascular rejection. Transplantation. 51:1991;312-315.
27. Szczech L.A., Berlin J.A., Aradhye S., Grossman R.A., Feldman H.I. Effect of anti-lymphocyte induction therapy on renal allograft survival: a meta-analysis. J. Am. Soc. Nephrol. 8:1997;1771-1777.
28. Toronyi E., Remport A., Jaray J., Mathe Z., Borka P., Perner F. Evaluation of various immunosuppressive regimes in second renal transplants. Transplant. Proc. 33:2001;2315-2316.
29. Zietse R., van Steenberge E.P., Hesse C.J., Vaessen L.B., IJzermans J.N., Weimar W. Single-shot, high-dose rabbit ATG for rejection prophylaxis after kidney transplantation. Transpl. Int. 6:1993;337-340.